Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
A-267 ATF/cAMP response element (CRE) in conjunction with a novel-248 ATF/CRE modifier (ACM), serving as a binding site for ATF4 and ATF3 transcription factors, regulates the activity of the basic ChaC1 promoter
and intravenously as an infusion
These are approximate ranges
Compounded medications do not go through the same premarket review as commercially manufactured drugs with approved applications
A master antioxidant
Reviewed at the July 2324, 2026 PCAC meeting, which voted to recommend it for the 503A bulks list (for ulcerative colitis) a non-binding recommendation, not authorization the FDA issues any final rule later, so it is not authorized for compounding
US$ 20.46
US$ 24.13
US$ 28.92
US$ 20.75
US$ 22.84
US$ 24.24
US$ 20.46
